CRyPTIC aim to help improve control of tuberculosis and facilitate WHO’s End TB Strategy by better, faster and more targeted treatment of drug-resistant tuberculosis via genetic resistance prediction, paving the way towards universal drug susceptibility testing (DST).

Our ultimate goal is to achieve sufficiently accurate genetic prediction of resistance to most of the anti-tuberculosis drugs, so that whole genome sequencing replaces culture-based DST for TB. This will enable rapid-turnaround near-to-patient assays to revolutionise MDR-TB identification and management.